In NAFLD models, MET treatment has been shown to manifest protective effects against the development of NAFLD in association with the improvement of inflammation markers such as IL-10, gut microbiota composition, and gut barrier integrity [44,45]. The gene discussed is IL10; the disease is metabolic dysfunction-associated steatotic liver disease.